Position in NVS
as of Jun 30, 2026
· filed Aug 18, 2026
Position Value
$1,073,532
+$27,195 QoQ
Shares Held
6,850
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#597
of 1,603 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Kimelman & Baird, LLC holds $87,529,146 across 10 Drug Manufacturers - General names. NVS ranks #6 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
40,384 | $48,437,785 | |
| 2 | MRK |
Merck & Co., Inc.
|
160,179 | $20,583,001 | |
| 3 | ABBV |
AbbVie Inc.
|
30,656 | $7,714,275 | |
| 4 | AMGN |
Amgen Inc
|
14,240 | $5,156,588 | |
| 5 | JNJ |
Johnson & Johnson
|
10,250 | $2,603,192 | |
| 6 | NVS |
Novartis AG
This page
|
6,850 | $1,073,532 | |
| 7 | PFE |
Pfizer Inc
|
42,976 | $1,034,862 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
15,525 | $894,550 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,073,532 | 6,850 | Shares | Sole | 2026-08-18 | |
| 2026-03-31 | $1,046,337 | 6,850 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $944,409 | 6,850 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $878,444 | 6,850 | Shares | Sole | 2025-11-25 | |
| 2025-06-30 | $828,918 | 6,850 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $763,638 | 6,850 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $666,573 | 6,850 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $787,887 | 6,850 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $734,574 | 6,900 | Shares | Sole | 2024-08-19 | |
| No filing history on record for this holder in this stock. | ||||||